Evaluation of the Danish Aerospace Corporation Portable Pulmonary Function System

Alan D. Moore, Jr., Ph.D.¹
Meaghan E. Downs, Ph.D.²
Alan H. Feiveson, Ph.D.³
Jamie R. Guined, M.S.⁴
Stuart M. C. Lee, Ph.D.²

¹Lamar University, Beaumont, TX
²KBRwyle, Houston, TX
³NASA Johnson Space Center, Houston, TX
⁴University of Houston, Houston, TX

February 2018
Since its founding, NASA has been dedicated to the advancement of aeronautics and space science. The NASA scientific and technical information (STI) program plays a key part in helping NASA maintain this important role.

The NASA STI program operates under the auspices of the Agency Chief Information Officer. It collects, organizes, provides for archiving, and disseminates NASA’s STI. The NASA STI program provides access to the NASA Aeronautics and Space Database and its public interface, the NASA Technical Report Server, thus providing one of the largest collections of aeronautical and space science STI in the world. Results are published in both non-NASA channels and by NASA in the NASA STI Report Series, which includes the following report types:

- **TECHNICAL PUBLICATION.** Reports of completed research or a major significant phase of research that present the results of NASA Programs and include extensive data or theoretical analysis. Includes compilations of significant scientific and technical data and information deemed to be of continuing reference value. NASA counterpart of peer-reviewed formal professional papers but has less stringent limitations on manuscript length and extent of graphic presentations.

- **TECHNICAL MEMORANDUM.** Scientific and technical findings that are preliminary or of specialized interest, e.g., quick release reports, working papers, and bibliographies that contain minimal annotation. Does not contain extensive analysis.

- **CONTRACTOR REPORT.** Scientific and technical findings by NASA-sponsored contractors and grantees.

- **CONFERENCE PUBLICATION.** Collected papers from scientific and technical conferences, symposia, seminars, or other meetings sponsored or co-sponsored by NASA.

- **SPECIAL PUBLICATION.** Scientific, technical, or historical information from NASA programs, projects, and missions, often concerned with subjects having substantial public interest.

- **TECHNICAL TRANSLATION.** English-language translations of foreign scientific and technical material pertinent to NASA’s mission.

- Specialized services also include creating custom thesauri, building customized databases, and organizing and publishing research results.

For more information about the NASA STI program, see the following:

- Access the NASA STI program home page at [http://www.sti.nasa.gov](http://www.sti.nasa.gov)
- E-mail your question via the Internet to help@sti.nasa.gov
- Fax your question to the NASA STI Help Desk at 443-757-5803
- Phone the NASA STI Help Desk at 443-757-5802
- Write to:
  NASA STI Help Desk
  NASA Center for AeroSpace Information
  7115 Standard Drive
  Hanover, MD 21076-1320
Evaluation of the Danish Aerospace Corporation Portable Pulmonary Function System

Alan D. Moore, Jr., Ph.D.¹
Meghan E. Downs, Ph.D.²
Alan H. Feiveson, Ph.D.³
Jamie R. Guined, M.S.⁴
Stuart M. C. Lee, Ph.D.²

¹Lamar University, Beaumont, TX
²KBRwyle, Houston, TX
³NASA Johnson Space Center, Houston, TX
⁴University of Houston, Houston, TX

National Aeronautics and Space Administration

Johnson Space Center Houston,
Texas 77058

February 2018
### TABLE OF CONTENTS

**ABSTRACT** .............................................................................................................................................................. 6

**INTRODUCTION** .................................................................................................................................................... 7

**METHODS** ............................................................................................................................................................... 8

- **SUBJECTS** ............................................................................................................................................................... 8
- **OVERALL PROTOCOL** ............................................................................................................................................. 8
- **METABOLIC GAS ANALYSIS SYSTEMS** .................................................................................................................. 9
- **CARDIAC OUTPUT MEASUREMENTS** ...................................................................................................................... 9
- **STATISTICAL METHODS** ...................................................................................................................................... 10

**RESULTS** ............................................................................................................................................................... 10

- **SUBMAXIMAL EXERCISE** ....................................................................................................................................... 10
- **MAXIMAL EXERCISE** ............................................................................................................................................ 13
- **CARDIAC OUTPUT** ................................................................................................................................................ 13

**DISCUSSION** ......................................................................................................................................................... 15

- **LIMITATIONS** ....................................................................................................................................................... 16

**CONCLUSIONS** ..................................................................................................................................................... 16

**ACKNOWLEDGMENTS** ....................................................................................................................................... 18

**REFERENCES** ....................................................................................................................................................... 19

**APPENDIX A – ACRONYM LIST** ...................................................................................................................... 21
ABSTRACT

A research project designed to investigate changes in maximal oxygen consumption (VO2max) during and following long duration flight on the International Space Station (ISS) has recently been completed. The device used to measure oxygen consumption (VO2) on board ISS, the Portable Pulmonary Function System (PPFS) manufactured by the Danish Aerospace Corporation (DAC), is based on previous-generation devices manufactured by DAC, but the PPFS has not been validated for analyzing metabolic gases or measuring cardiac output (Qc). The purpose of the present evaluation is to compare PPFS metabolic gas analysis measurements to measurements obtained using a clinically-validated system (ParvoMedics TrueOne© 2400 system; Parvo). In addition, Qc data collected with the PPFS were compared to Qc measurements from echocardiography. METHODS: Ten subjects completed three cycle exercise tests to maximal exertion. The first test was conducted to determine each subject’s VO2max and set the work rates for the second and third (comparison) tests. The protocol for the two comparison tests consisted of three five-minute stages designed to elicit 25%, 50%, and 75% VO2max (based upon results from the initial test), followed by one-minute stages of increasing work rate (25 watts/minute) until the subject reached maximal effort. During one of the two comparison tests, metabolic gases and Qc were assessed with the PPFS; metabolic gases and Qc were assessed with the Parvo and by echocardiography, respectively, during the other test. The order of the comparison tests was counterbalanced. VO2max and maximal work rate during the comparison tests were compared using t tests. Mixed-effects regression modeling was used to analyze submaximal data. RESULTS: All of the data were within normal physiological ranges. The PPFS-measured values for VO2max were 6% lower than values obtained with the Parvo (PPFS: 3.11 ± 0.75 L/min; Parvo: 3.32 ± 0.87 L/min; mean ± standard deviation; P = 0.02); this difference is probably due to flow restriction imposed by the PPFS Qc accessories. Submaximal VO2 values were slightly lower when measured with the PPFS, although differences were not physiologically relevant. The PPFS-measured values of submaximal carbon dioxide production (VCO2) were lower than the data obtained from Parvo, which could be attributed to lower fractions of expired carbon dioxide measured by the PPFS. The PPFS Qc values tended to be lower than echocardiography-derived values. CONCLUSIONS: The results of the present study indicate a need to further examine the PPFS and to better quantify its reproducibility; however, none of the findings of the current evaluation indicate that the PPFS needs to be modified.
INTRODUCTION

The National Aeronautics and Space Administration (NASA) Human Research Program (HRP) has developed an integrated research plan to address the health risks that might impede human exploration beyond Earth’s orbit (Human Research Program Integrated Research Plan, NASA HRP 47065). One of the risks identified by NASA’s Integrated Research Plan is the “Risk of reduced physical performance capabilities due to reduced aerobic capacity.”

Maximal oxygen uptake (VO₂max), also known as aerobic capacity, is the maximal rate at which a person can consume oxygen (O₂) during exercise, and is directly related to the ability to perform prolonged and strenuous work (1, 2). There is clear evidence from bed rest studies (10) and short-duration spaceflight that VO₂max is reduced after exposure to both simulated and actual microgravity (12, 16), particularly when minimal or no exercise is performed during the exposure period. However, results from longer spaceflight missions, based upon submaximal exercise test results, have been less clear. During the Skylab missions, submaximal exercise testing was performed approximately every six days, and there appeared to be no overall trend (increase or decrease) in the heart rate (HR) response to standard exercise work rates (up 75% of pre-flight VO₂max). These results were interpreted to indicate that VO₂max was unchanged during missions up to three months in duration (14, 15, 21). Similar submaximal exercise tests were performed each month during early ISS missions. In contrast to Skylab results, ISS crewmembers experienced an elevated HR response to exercise in the first weeks of the mission, which suggested that VO₂max may have been compromised, but there appeared to be some recovery over the course of a six-month mission (18). In the first week after landing, the HR responses to exercise of both the Skylab and ISS crew members were elevated, which is consistent with a decline in VO₂max. Multiple factors other than aerobic deconditioning can influence the HR response to exercise and given the error in estimating VO₂max from submaximal exercise data (11), it was unclear until recently (16) how much, or even if, VO₂max is affected by long-duration spaceflight.

Oxygen uptake during exercise (VO₂) is influenced by both central (related to the heart) and peripheral (related to O₂ extraction and distribution of blood flow in the muscle tissues) factors. The relationship between these factors is expressed in a relation commonly known as the Fick equation (20):

\[ \text{VO}_2 = Q_e (a-v)O_2 \text{ difference} \]

in which cardiac output (Qₑ) is the amount of blood pumped from the heart’s left ventricle per minute and is the product of HR and the volume of blood ejected from the left ventricle per beat (also known as stroke volume [SV]). Arterial to venous O₂ difference “(a-v)O₂” is the difference between O₂ levels in the arterial and venous blood, i.e. O₂ extraction of the tissues. Thus, any factor that influences HR, SV, or O₂ extraction may influence VO₂ or VO₂max.

A contractor to the European Space Agency, Damec Research ApS (currently named Danish Aerospace Corporation [DAC]), developed a metabolic gas analysis system capable of measuring VO₂ on board ISS. This device, named the Portable Pulmonary Function System (PPFS), was used to measure astronauts’ VO₂max during long-duration space flight (16). The current report describes our efforts to validate measurements obtained from the PPFS by comparing PPFS measurements of metabolic gas analysis obtained during exercise tests with equivalent measurements obtained using the ParvoMedics TrueOne© 2400 system (ParvoMedics, Sandy, UT). The ParvoMedics system has been validated (8) for accurate measurement of VO₂ and has been used in the Exercise Physiology Laboratory at NASA Johnson Space Center since 2004 but was not designed for use on ISS. The second purpose of the present study was to compare the non-invasive measurements of Qₑ obtained by the PPFS to measurements obtained using echocardiography.
METHODS

Subjects

Ten healthy volunteers participated in the ground-based study described here (Table 1). Subjects passed a modified Air Force Class III physical exam before they participated in the study and received written and verbal explanations of test protocols before providing written informed consent. The NASA Johnson Space Center Committee for the Protection of Human Subjects reviewed and approved the test protocols and procedures.

<table>
<thead>
<tr>
<th>TABLE 1: SUBJECT CHARACTERISTICS (MEAN ± SD) BY SEX.</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
</tr>
<tr>
<td>Age (yr)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Height (cm)</td>
</tr>
<tr>
<td>VO2max (ml/kg/min)</td>
</tr>
</tbody>
</table>

Overall Protocol

Subjects performed three peak cycle tests to measure VO2max. The LODE Excalibur Sport (Groningen, NL) cycle ergometer was used for all testing.

The initial peak cycle test used the same protocol used to measure the pre-flight VO2max in astronauts before early ISS missions (18). During the initial test, subjects with a body mass of > 65 kg cycled for three minutes each at 50, 100, and 150 watts (W), after which work rate was increased 25 W/minute until maximal exertion. If the subject’s body mass was < 65 kg, the subjects cycled for three minutes each at 50, 75, and 100 W, after which work rate increased 25 W/minute until maximal exertion. If an individual who was <65 kg reported that they regularly participated in cycle exercise, the first protocol described above was used for this initial test. For either protocol, the work rate was increased until subjects indicated that they could no longer continue or until they could no longer maintain a pedal cadence of 75 revolutions per minute. During this initial test, the ParvoMedics TrueOne© (ParvoMedics, Salt Lake City, UT) system was used to perform metabolic gas analysis. The VO2 and work rate data from the initial test were used to design the protocol for the second and third (comparison) tests.

The second and third tests were designed to compare the metabolic gas analysis and Qc measurements from the two different devices. The testing protocol for these comparison tests was based on the submaximal cycle test used by Skylab astronauts (14, 15, 21) and for the ISS Periodic Fitness Evaluation during early ISS mission (18), but the protocol was extended to achieve VO2max. Specifically, the protocol for the comparison tests consisted of three five-minute stages designed to elicit 25%, 50%, and 75% of the individual’s VO2max that was previously determined from the initial peak cycle test. The three initial stages were followed by work rate increases of 25 W/minute until subjects reached their maximal effort. This is the same exercise protocol that was used in a study of ISS astronauts (16). Comparison tests were performed in a counterbalanced order; one test was performed using the ParvoMedics TrueOne© system paired with echocardiography to measure Qc, and one test was performed using the PPFS to obtain metabolic gas analysis data and Qc measurements using a rebreathing technique. These tests were repeated within one month of the initial test, and the two tests were separated by at least one week to minimize the potential effects of residual soreness or fatigue.

Before starting the exercise, the subjects rested quietly for five minutes in supine and seated positions while measurements of HR, heart rhythm, and blood pressure (BP) were taken. HR and rhythm were measured electrocardiographically (Q-Stress, Quinton Instruments, Seattle, WA), and BP
was measured using a mercurial sphygmomanometer and stethoscope. HR, heart rhythm, and metabolic expired gas were measured continuously throughout the test. BP was measured once during each submaximal exercise stage, and ratings of perceived exertion (5) were reported during the last 30 seconds of each stage. BP was recorded during the recovery period after the test, and the subject was monitored for any adverse effects caused by maximal physical exertion.

**Metabolic Gas Analysis Systems**

The dependent variables for comparisons between the two systems were VO₂, carbon dioxide production (VCO₂), expired ventilation (Vₑ), and fractions of expired oxygen and carbon dioxide (FEO₂ and FECO₂).

ParvoMedics TrueOne© system uses a paramagnetic O₂ analyzer (operating range 0-25% O₂) and an infrared single-beam, single-wavelength, carbon dioxide (CO₂) analyzer (operating range 0-15% CO₂) to measure the composition of expired gases. The subjects inspired through a two-way non-rebreathing valve (Hans Rudolph Model 2700, Kansas City, MO) and expired air composition was sampled from a four-liter mixing chamber. The inspired gas composition was assumed to be standard atmospheric values (i.e., 20.93% O₂ and 0.03% CO₂). Vₑ was measured using a Hans Rudolph Model 3813 linear pneumotachometer (operating flow range 0-800 L/min). Computational software was provided with the system. Data were collected continuously by the ParvoMedics system and were averaged in 30-second intervals to the nearest whole breath. VO₂max was accepted as the highest VO₂ attained for a single 30-second period.

The PPFS uses two types of technology for gas analysis. A photoacoustic method of gas analysis is used to measure CO₂ concentration. In this technique, the gas sample is exposed to intermittent infrared light. The gas sample absorbs the light, and the heat from the absorbed energy results in an increase in pressure in the sample chamber. The intermittent infrared light is divided into different pulsation frequencies and is filtered optically. Each optical filter allows only specific wavelengths of light to pass through. The wavelengths correspond to the infrared absorption spectra of the sample gases. When the light source is removed the gas cools down, resulting in a pressure fluctuation. Because the pulsation frequency is in the audible range, the pressure fluctuation becomes an acoustic signal that is detected by a microphone. The sounds recorded by the microphone are analyzed, and the amplitude of each signal is used to calculate the gas concentration. The PPFS operating range for CO₂ concentration is from 0% to 12%. An Oxigraf™ sensor in the PPFS is used for O₂ analysis. The Oxigraf™ uses a spectroscopy technique for laser diode absorption in which the sample gas is exposed to a laser with a wavelength of 760 nm (the peak of O₂ absorption). The laser signal is attenuated in proportion to the concentration of O₂ present in the sample. The PPFS operating range for O₂ is from 0% to 100%. When using the PPFS during exercise testing, the subject inspires through a DAC custom-designed two-way non-rebreathing valve and the expired gases are sampled in a 15-liter anesthesia bag that serves as a mixing reservoir. Ventilation is measured on the inspired side of the non-rebreathing valve using a DAC custom-designed pneumotach (operating flow range 0-900 L/min). The technologies used for PPFS metabolic gas analysis are further described by Clemensen and colleagues (6). A proprietary software package developed by DAC, named ADAM, was used to compute metabolic gas analysis variables. Similar to the ParvoMedics data reduction, the data were averaged in 30-second intervals to the nearest whole breath.

**Cardiac Output Measurements**

To obtain Qc measurements from echocardiography, two-dimensional imaging was used to obtain the aortic annulus diameter (d) from the parasternal long axis during supine rest before the exercise tests. Continuous-wave Doppler from the apical window (2- to 4-MHz phase array probe, iE33, Phillips Ultrasound, Andover, MA) was used to obtain aortic blood velocity time integral in three to five heartbeats during the last minute of rest and each five-minute exercise stage. Images were stored digitally for offline analysis and independently analyzed by two experienced, registered sonographers.
Aortic annulus area ($\pi d^2/4$), stroke volume (annulus diameter x velocity time integral), and $Q_c$ (stroke volume x heart rate) were calculated.

$Q_c$ measurements using the PPFS involved subjects rebreathing into and out of a bag containing 2.5-3.5 liters of a gas composed of 1% Freon R-22, 1% sulfur hexafluoride (SF$_6$), 40% O$_2$, and 58% N$_2$. The subjects started the rebreathing procedure after an exhalation at a self-selected time point during seated rest and within the last minute of each five-minute stage of exercise. The rebreathing protocol consisted of eight breaths (approximately 30 seconds during rest and 20 to 25 seconds during exercise). The ADAM software calculated $Q_c$ using formulas that are described elsewhere (4). Briefly, $Q_c$ was calculated using the rate of disappearance of Freon R-22 (a blood-soluble gas) from the rebreathed air as measured from the end-tidal expiratory gas fractions. Adequate gas mixing in the lungs, required for accurate $Q_c$ measurements, was determined by measuring the end-tidal expiratory gas fractions of SF$_6$ (a blood-insoluble gas). Freon R-22 and SF$_6$ were sampled through a Nafion® catheter connected to a port adjacent to the mouthpiece of the PPFS.

**Statistical Methods**

The PPFS measures were compared to those obtained with the Parvomedics device using expected and actual responses to a range of workloads experienced by the subjects during submaximal exercise. To achieve this comparison, we used mixed-effects regression models (7) to estimate the mean output of gas measurements ($VO_2$, $VCO_2$, $VE$, $FEO_2$ and $FECO_2$) obtained on the Parvomedics device as either a linear or a quadratic function of work rate (depending on the type of output), allowing for random subject differences and within-subject measurement errors. We then used another mixed-effects regression model to estimate the bias (mean difference between the two devices: PPFS − Parvomedics) as a function of the mean. From this second regression model, we also calculated 95% confidence limits for the bias, which are displayed for each of the measurements. The plots are similar to Bland-Altman plots (3), except that in our case, by modeling the physiological responses as functions of workload, we make allowance for repeated measures on subjects as well as reduce sensitivity to the effect of measurement errors in the standard device (in this case, the Parvomedics). The mean $VO_2$max and maximal work rate attained during the tests with each device were also compared using paired $t$ tests.

The analysis of the PPFS and echocardiographic $Q_c$ and SV data followed a strategy similar to that used for the metabolic gas analysis comparisons, with one important difference: because there is no compelling evidence in the literature to suggest that either of the methods should serve as a standard (17), the data collected from each device was modeled as a function of cycle ergometer work rate.

**RESULTS**

**Submaximal Exercise**

All of the metabolic gas analysis data, irrespective of the device used for measurement, were within normal physiological ranges. Thus, there were no gross errors in output from either the PPFS or the Parvomedics system.

Comparisons of the absolute $VO_2$ values measured by the two devices are shown in Figure 1. In general, the PPFS-measured values were lower than those measured by the Parvomedics system.
Figure 1. VO₂ values observed during the submaximal stages of testing. The left panel displays the observed differences (PPFS-Parvomedics) between the two devices. Expected VO₂ (x-axis) for each exercise level is predicted from the relationship between VO₂ and work rate for these subjects, as measured by the Parvomedics (the “clinical standard” device). The numbers displayed next to the data points are subject identifiers (three data points for each subject). The gray shaded area indicates ±5% of the expected VO₂. The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the VO₂ values of the two devices evaluated. The solid line is the line of identity.

The VO₂ data are displayed in Figure 2. As was the case for VO₂, the PPFS values were lower than the data measured by the Parvomedics system. The disparity between the two devices increased as the values of VO₂ rose.

Figure 2. VCO₂ values observed during the submaximal stages of testing. The left panel displays the observed differences (PPFS-Parvomedics) between the two devices. Expected VCO₂ (x-axis) for each exercise level was predicted from the relationship between VCO₂ and work rate for these subjects, as measured by the Parvomedics device. The numbers displayed next to the data points are subject identifiers (three data points for each subject). The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the VCO₂ values of the two devices evaluated. The solid line is the line of identity.

Figure 3 illustrates the ventilation data. The values from the PPFS and the Parvomedics were quite close; the 95% confidence intervals of the difference between the two devices contained zero (no difference) throughout the range of data observed in the evaluation.
**Figure 3.** $V_E$ values observed during the submaximal stages of testing. The left panel displays the observed differences (PPFS-Parvomedics) between the two devices. Expected $V_E$ (x-axis) for each exercise level is predicted from the relationship between $V_E$ and work rate for these subjects, as measured by the Parvomedics. The numbers displayed next to the data points are subject identifiers (three data points for each subject). The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the $V_E$ values of the two devices evaluated. The solid line is the line of identity.

The FEO$_2$ measured by each device was fairly comparable (**Figure 4**). At the very lowest levels, the 95% confidence interval was slightly above a difference of zero, which indicates that the PPFS values were slightly higher than the Parvomedics values. This would cause computed VO$_2$ values from the PPFS to be lower.

**Figure 4.** FEO$_2$ values observed during the submaximal stages of testing. The left panel displays the observed differences (PPFS-Parvomedics) between the two devices. Expected FEO$_2$ (x-axis) for each exercise level is predicted from the relationship between FEO$_2$ and work rate for these subjects, as measured by the Parvomedics. The numbers displayed next to the data points are subject identifiers (three data points are present for each subject). The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the FEO$_2$ values of the two devices evaluated. The solid line is the line of identity.

FECO$_2$ values are illustrated in **Figure 5**. The PPFS values were clearly lower than the Parvomedics values across the range of data produced by our subjects.
Figure 5. FECO₂ values observed during the submaximal stages of testing. The left panel displays the observed differences (PPFS-Parvomedics) between the two devices. Expected FECO₂ (x-axis) for each exercise level is predicted from the relationship between FECO₂ and work rate for these subjects, as measured by the Parvomedics. The numbers displayed next to the data points are subject identifiers (three data points for each subject). The solid line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the FECO₂ values of the two devices evaluated. The solid line is the line of identity.

Maximal Exercise

The average VO₂max attained by the subjects was higher when measurements were obtained with the Parvomedics device (Figure 6). The higher Parvomedics VO₂max also was associated with a higher peak work rate attained during testing.

Figure 6. Mean VO₂max (left panel) and maximal cycle work rate (right panel) attained during the tests using the Parvomedics and PPFS devices. Note that the PPFS trial produced a lower VO₂max in almost direct proportion to the lower work rate attained.

Cardiac Output

The Qc values obtained from the PPFS and echocardiographically are displayed in Figure 7. At resting levels the two methods provided comparable data; however, with increasing exercise work rate the echocardiographic data were lower than the associated PPFS data.
**Figure 7.** $Q_C$ values observed during the submaximal stages of testing. The left panel displays the differences (PPFS-Echocardiograph) observed between the two devices across exercise work rates (0 W = seated rest). The numbers displayed next to the data points are subject identifiers (three data points for each subject). The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the $Q_C$ values of the two methods evaluated. The solid line is the line of identity.

**Figure 8.** SV values observed during the submaximal stages of testing. The left panel displays the differences (PPFS-Echocardiograph) observed between the two devices across exercise work rates (0 W = seated rest). The numbers displayed next to the data points are subject identifiers (three data points for each subject). The solid straight line is the mean relationship, and the curves are 95% confidence intervals for the mean difference. The right panel displays the relationship between the SV values of the two methods evaluated. The solid line is the line of identity.

**Figure 8 contains the SV data from the echocardiograph and the PPFS.** Stroke volume tended to be higher when measured by echocardiography, with the margin of the upper 95% confidence interval falling close to no difference across the range of values measured.
DISCUSSION

The primary purpose of this study was to determine whether consistent differences existed between two metabolic gas analysis systems, PPFS and Parvomedics, with respect to measuring VO\textsubscript{2} during submaximal and maximal exercise. We also assessed differences between Qc measurements obtained with the PPFS and by echocardiography.

Our data show statistically significant differences between the PPFS and Parvomedics values of VO\textsubscript{2} during submaximal exercise at loads up to 75% VO\textsubscript{2max} (Figure 1), but this difference is not of sufficient magnitude to be physiologically important. The average differences observed in submaximal VO\textsubscript{2} were just outside the 4%-6% intra-individual day-to-day variation in VO\textsubscript{2} commonly reported in the literature (19). The upper 95% confidence interval computed from the differences between the two devices was not outside of the 4%-6% range. However, when measurements are repeated across the duration of a longitudinal study, it is important that all measurements (e.g., before, during, and after space flight) be conducted using the same device to avoid potential sources of error associated with different metabolic gas analysis systems.

It appears that the difference in submaximal VO\textsubscript{2} values was not caused by different measures of V\textsubscript{E} obtained by the two devices (Figure 3). This suggests that FEO\textsubscript{2} measurements might explain the VO\textsubscript{2} differences; conceptually VO\textsubscript{2} is simply the product of V\textsubscript{E} and the difference in O\textsubscript{2} concentration between ambient air and expired air. However, it is difficult to pinpoint this as the precise cause of the discrepancy in VO\textsubscript{2} values because the preponderance of the FEO\textsubscript{2} data is clustered within a narrow range between 16 and 16.5% O\textsubscript{2} (Figure 4). FECO\textsubscript{2} also contributes to the calculation of VO\textsubscript{2}, but its influence is negligible compared to FEO\textsubscript{2} or V\textsubscript{E}. To illustrate, at a VO\textsubscript{2} of 4.68 L/min (a level representative of maximal exercise of our fittest subjects) if FECO\textsubscript{2} was reduced by 0.4% (which is the average difference observed in FECO\textsubscript{2} between the two devices in our tests; Figure 5), the calculated VO\textsubscript{2} would be reduced only to 4.66 L/min.

Mean VO\textsubscript{2}max obtained from the two devices was significantly different (Figure 6). However, this is not likely due to any measurement problems within the devices per se, in light of the fact that the 6.1% lower VO\textsubscript{2max} measured with the PPFS was observed in combination with a 6.7% reduction in the peak work rate attained during the PPFS tests. The reduction in work rate achieved by the subjects during the PPFS comparison test might be due to a ventilatory flow restriction imposed by the PPFS. When using the PPFS, the subjects breathe through a valve and a mouth port tube that is lengthened to accommodate the Qc rebreathing bag adapter and the pneumatic valve, which controls flow into and out of the bag. The extended length of the port tube causes more flow limitation and resistance to breathing than the standard Hans Rudolph 2700 valve that is part of the Parvomedics device. Pressures in the respiratory valve up to 13.5 cmH\textsubscript{2}O were measured by the PPFS during peak exercise, and the pressure during submaximal exercise ranged from 2 to 5 cmH\textsubscript{2}O. A peak pressure of about 8 cmH\textsubscript{2}O is expected at peak exercise ventilation values when using the Hans Rudolph 2700 valve (http://www.rudolphke.com/pdf/691017%201008%201.pdf). The pressures measured by the PPFS do not seem to be in the range that would cause marked limitation to submaximal exercise, although ventilation at maximal exercise levels may be impaired (9), thus limiting performance.

The differences in VCO\textsubscript{2} values obtained from the two devices (Figure 2) are likely to be directly attributable to the different FECO\textsubscript{2} data (Figure 5). The primary contributing variables used in the calculation of VCO\textsubscript{2} are V\textsubscript{E} and FECO\textsubscript{2}. As noted above, V\textsubscript{E} measurements did not differ significantly between the two devices. The disparity between FECO\textsubscript{2} values measured by the Parvomedics device and the PPFS are not easily explainable because both systems use infrared measuring techniques for detecting CO\textsubscript{2} concentrations.

Qc and SV values obtained during exercise using the PPFS are lower than the measurements obtained by echocardiography (Figures 7 and 8). As noted in the statistical methods section of this report and in previous reports (17), there is no compelling evidence to suggest that one technique is more
accurate or valid than the other. However, in the present study, measurement of SV and Qc using echocardiography involved analysis of as few as three heart beats, whereas about 20 to 40 heart beats would occur during the rebreathing technique used for the PPFS. In addition, it becomes increasingly difficult to attain accurate ultrasound images with increasing cycle work rate because of subject movement. Thus, it is possible that the rebreathing technique was less prone to variation than echocardiography because beat-to-beat differences in SV are averaged over more heart beats and subject movement does not affect the measurement.

**Limitations**

An ideal comparison of metabolic gas analysis systems would entail the two systems being operated “in series” (i.e., measuring fractions and volumes of the same expired gases or from sensors in close proximity to one another) on the same subject. An “in series” evaluation eliminates day-to-day variation in the subjects’ response to exercise as a source of error. However, this type of setup often is not feasible because the two systems can interfere with each other and produce erroneous results. Discussions with the manufacturers of both the Parvomedics system and the PPFS led us to conclude that an evaluation with the two devices in series may lead to errors, particularly in gas sampling, and therefore our tests were performed using the devices on separate days. With this approach, valid comparisons of the VO₂ and VCO₂ data obtained from each device are still possible, although variables associated with the calculation of VO₂ and VCO₂ (i.e., FEO₂, FECO₂ and VE) need to be assessed with caution. For example, an individual should have a similar VO₂ response to a similar exercise load during two separate tests (an expected finding), but VE could be higher in one trial and resulting in a higher FEO₂ (13). Alternatively, we could have exchanged the PPFS and Parvomedics at the midpoint during a series of prolonged exercise stages. This approach would have eliminated day-to-day variation during submaximal data collections, but it would have introduced the distinct disadvantage of not being able to compare maximal responses; only one device could be used at a time to collect maximal exercise data. Therefore, the approach that we selected appeared to be the best compromise. However, although the data from our evaluation indicate that FEO₂ values may differ, and the FECO₂ values certainly differ, there is no way to conclusively prove this using the present data set.

The difference between VO₂max data obtained on the two devices is likely a limitation of the PPFS design. If Qc measurements are not desired, the PPFS can be used without the extended mouth-port adapter. This should reduce the flow limitation and allow subjects to exercise to higher loads. However, because one of the objectives of the ISS study (16) was to measure Qc, this is not viewed as an ideal solution.

It should be noted that throughout this report VO₂ measured at maximal exertion during the peak cycle tests has been referred to as VO₂max. This is technically not the correct terminology for our measurement because we performed no specific verification of a plateau in VO₂ with increasing work rates, which is the criterion for “true” VO₂max (22). However, not all individuals can attain this plateau, and previous comparisons have reported no statistically significant difference between VO₂max and peak VO₂, which is the correct description for the variable reported here. Further, because the terms “VO₂max” and “peak VO₂” have been used interchangeably in various spaceflight and bed rest publications, we have chosen to use only VO₂max in the description of test results contained in this report.

**CONCLUSIONS**

There were no findings in this evaluation that preclude using the PPFS to obtain data before, during, or after ISS missions. In light of the differences observed in the VO₂ and VCO₂ measurements obtained by the PPFS and the Parvomedics devices, it is imperative that the same device be used for all pre-, in-, and post-flight testing if the data are to be compared across time points.

- The differences observed in submaximal VO₂ were small and are probably not clinically relevant.
• The differences observed in submaximal VCO₂ are very likely due to differences in FECO₂. Although FECO₂ has only a small effect on the computation of VO₂, the effect could confound any research projects that examine VCO₂ as a variable of interest. We recommend that PPFS expired gas fraction measurements be further examined.

• The reduced VO₂max and maximal work rate attained by the subjects during PPFS tests are likely due to a ventilatory flow limitation.

• The reproducibility of the PPFS measurements should be quantified.
ACKNOWLEDGMENTS

The authors gratefully acknowledge the contributions of the members of the Exercise Physiology and Countermeasures Project, the Cardiovascular and Vision Laboratory, and the test subjects for their participation in this evaluation.

Dr. Alan Moore, formerly of Wyle Science, Technology, and Engineering, now is an Associate Professor in the Department of Health and Kinesiology at Lamar University in Beaumont, TX. Jamie Guined, formerly of University of Houston, now is a Senior Scientist at SeaSpace Exploration & Research, LLC.

This document was created in collaboration with the Medical System Concept of Operations for Mars Exploration Missions team: Melinda Hailey, BSN, RN, David Reyes, MD, David Rubin, and Michelle Urbina.

Definitions and example actions were reviewed by ExMC’s Exploration Clinical Working Group (ECWG) and the Space Medicine Operations Division’s Medical Operations Group (MOG).
REFERENCES


<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>CO2</td>
<td>Carbon Dioxide</td>
</tr>
<tr>
<td>ECWG</td>
<td>Exploration Clinical Working Group</td>
</tr>
<tr>
<td>FECO2</td>
<td>Fractions of Expired Carbon Dioxide</td>
</tr>
<tr>
<td>FEO2</td>
<td>Fractions of Expired Oxygen</td>
</tr>
<tr>
<td>HRP</td>
<td>Human Research Program</td>
</tr>
<tr>
<td>ISS</td>
<td>International Space Station</td>
</tr>
<tr>
<td>MOG</td>
<td>Medical Operations Group</td>
</tr>
<tr>
<td>NASA</td>
<td>National Aeronautics and Space Administration</td>
</tr>
<tr>
<td>O2</td>
<td>Oxygen</td>
</tr>
<tr>
<td>PPFS</td>
<td>Portable Pulmonary Function System</td>
</tr>
<tr>
<td>Qc</td>
<td>Cardiac Output</td>
</tr>
<tr>
<td>SF6</td>
<td>Sulfur Hexafluoride</td>
</tr>
<tr>
<td>SV</td>
<td>Stroke Volume</td>
</tr>
<tr>
<td>V_E</td>
<td>Expired Ventilation</td>
</tr>
<tr>
<td>VCO2</td>
<td>Submaximal Carbon Dioxide</td>
</tr>
<tr>
<td>VO2</td>
<td>Oxygen Consumption</td>
</tr>
<tr>
<td>VO2max</td>
<td>Maximal Oxygen Consumption</td>
</tr>
<tr>
<td>W</td>
<td>Watt</td>
</tr>
</tbody>
</table>